GPR110 overexpression increases tumorigenic potential of HER2+breast cancer cells

被引：1
|
作者：
Trivedi, M. V.
Bhat, R.
Yadav, V.
Yadav, P.
Ai-Rawi, A.
Christiny, P.
Nanda, S.
Giuliano, M.
Creighton, C.
Osborne, C. K.
Narkar, V. A.
Schiff, R.
机构：
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dan L Duncan Canc Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Univ Texas Houston, Inst Mol Med, Ctr Metab & Degenerat Dis, Houston, TX USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-P6-04-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-04-05
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COSTS OF RECURRENCE IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Albanell, J.
    Colomer, R.
    Martin, M.
    Martinez, D.
    Arroyo, I
    Moreno, E.
    VALUE IN HEALTH, 2020, 23 : S435 - S435
  • [42] The potential markers of endocrine resistance among HR+/HER2+breast cancer patients
    Chen, K.
    Quan, J.
    Yang, J.
    Chen, Z.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04): : 576 - 584
  • [43] HER2+breast cancer treatment and cardiotoxicity: monitoring and management
    Jerusalem, Guy
    Lancellotti, Patrizio
    Kim, Sung-Bae
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (02) : 237 - 250
  • [44] The Hierarchical Modular Structure of HER2+Breast Cancer Network
    Antonio Alcala-Corona, Sergio
    Espinal-Enriquez, Jesus
    de Anda-Jauregui, Guillermo
    Hernandez-Lemus, Enrique
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [45] AXL is a potential druggable target in trastuzumab resistance in HER2+breast cancer patients.
    Adam-Artigues, Anna
    Cervera, Raimundo
    Javier Arenas, Enrique
    Braso-Maristany, Fara
    Martinez-Sabadell, Alex
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Simon, Soraya
    Poveda, Jesus
    Burgues, Octavio
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Eroles, Pilar
    Prat, Aleix
    Arribas, Joaquin
    Miguel Cejalvo, Juan
    CANCER RESEARCH, 2021, 81 (13)
  • [46] Breast MRI as a radiomic biomarker of immune response in HER2+breast cancer
    Kennedy, Laura Carpin
    Durenberger, Grace
    Stanton, Sasha E.
    Vinayak, Shaveta
    Dintzis, Suzanne
    Partridge, Savannah
    Gadi, V. K.
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+breast cancer cells
    Qin, Lanfang
    Hahn, Maria B.
    Fu, Xiaoyong
    Shea, Martin J.
    Giuliano, Mario
    Nanda, Sarmistha
    Xu, Xiaowei
    Hu, Huizhong
    Jung, Sung Yun
    Heiser, Laura M.
    Wang, Nicholas
    Gray, Joe W.
    Hilsenbeck, Susan G.
    Creighton, Chad
    Shaw, Chad A.
    Chamness, Gary C.
    Edwards, Dean P.
    Herrera, Sabrina
    Gutierrez, Carolina
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [48] Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells
    Murad, Rabi
    Avanes, Arabo
    Ma, Xinyi
    Geng, Shuhui
    Mortazavi, Ali
    Momand, Jamil
    GENE, 2021, 799
  • [49] Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+breast cancer cells
    Karakas, Bahriye
    Ozmay, Yeliz
    Basaga, Huveyda
    Gul, Ozgur
    Kutuk, Ozgur
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2018, 1865 (08): : 1073 - 1087
  • [50] HER2-related biomarkers in HER2+breast cancer patients in Asia Pacific
    Kim, S-B
    Tsang, J.
    Kim, T-Y
    Yap, Y. S.
    Cornelio, G.
    Gong, G.
    Paik, S.
    Lee, S.
    Ng, T-Y
    Park, S.
    Oh, H-S
    Yau, T.
    Lee, S. H.
    Lim, J. H.
    Choi, Y-J
    Lee, E. M.
    Park, K-H
    Do, I-G
    Yeoh, E-M
    Ro, J.
    CANCER RESEARCH, 2013, 73
12345